Astragaloside II

Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis^{[1][2][3][4][5]}. In Vitro:Astragaloside II (0.1 nM-10 μM; 48-72 h) significantly promotes the cell viability of rat primary osteoblasts in a concentration-dependent manner^[1].
Astragaloside II (10-30 nM; 48-96 h) significantly enhances the proliferation of primary splenocytes induced by ConA, alloantigen or anti-CD3^[3].
Astragaloside II (80 μM; 48 h) sensitizes Bel-7402/FU cells to 5-fluorouracil (HY-90006)-induced cell death via suppression of autophagy^[4].
Astragaloside II (1 μM; 48 h) inhibits the levels of HIF-α, p-p65 and p-IκB in Lipopolysaccharide-stimulated CCD-18Co cells, exerting an anti-inflammatory effect^[5].
In Vivo:Astragaloside II (30-50 mg/kg; p.o.; once per day; 10 days) alleviates the symptoms of DSS (HY-116282)-induced ulcerative colitis in mice^[5].